Cathie Wood Still Interested In Psychedelics, She Bought Over 3 Million Atai Shares In July Alone

Several weeks ago, Cathie Wood's ARK Fund ARKG invested in the biotech psychedelics sector, specifically in major player Atai Life Sciences ATAI.  

The first purchase took place in February 2022, when ARK bought 83,278 shares of Atai Life Sciences. Less than two weeks later, the company acquired four times that, bringing its total ownership to over 340,000 shares, as first reported by Jason Najum on Microdose.

In early July 2022, the company’s spreadsheet showed it held a total 1,827,047 of Atai’s shares -representing an increase of more than 138,000 shares from March 2022. 

By mid-July, the total monthly investment was 621,812 shares. Yet ARK further acquired shares. Now it can be said that the total purchase of Atai stock for that month is over 3 million (3,018,751). 

Considering its rounding $4 for July, that’s $12 million invested in psychedelics by Cathie Wood’s fund, aka a noteworthy purchase from a celebrity investor

Photo Courtesy of Jeffrey Blum on Unsplash.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechCannabisNewsPenny StocksPsychedelicsSmall CapMarketsGeneralCathie WoodPsychedelics Investments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.


Loading...